In this new position paper « Digital Therapeutics – What Opportunities for Pharma Companies » which completes a Key Note published in June 2022, Smart Pharma Consulting:
- Defines DTx
- Describes DTx value for Patients, HCPs and the healthcare system
- Gives examples of typical applications
- Evaluates market determinants driving DTx attractiveness
- Describes DTx registration conditions in the USA and European Union
- Evaluates pharma companies’ determinants driving DTx attractiveness
- Analyses key opportunities and challenges for pharma companies
- Defines strategic options (around-the-pill vs. beyond-the-pill DTx)
- Reviews examples of DTx strategies implemented by pharma companies
- Provides an Advanced SWOT analysis (2022 – 2025)
- Makes recommendations.